Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Manchester United PLC (MANU) Price & Performance

AbCellera Biologics IncTrade
Manchester United PLCTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Manchester United PLC — how do they compare? AbCellera Biologics Inc trades at $9.96 (market cap $2.99B), while Manchester United PLC trades at $22.63 (market cap $3.80B). The key difference: Manchester United PLC is the larger of the two by market cap, and Manchester United PLC pays a 1.26% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLMANU
Market Cap
$2.99B$3.80B
Sector
HealthMedia
52-Week High
$9.76$23.53
52-Week Low
$2.78$15.10
Enterprise Value
$2.58B$4.74B
Dividend Yield
1.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.

The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.

Manchester United PLC

Manchester United (MANU) trades at $21.70, up 0.32% on the day, with a bearish technical signal but improving fundamentals. Recent Q1 2026 earnings beat expectations, though the company remains unprofitable with a net income margin of -2.65%. Key developments include securing land for a new 100,000-seat stadium and Champions League qualification, which may boost future revenue.

The outlook is mixed: operational improvements and stadium plans offer long-term growth potential, but persistent losses, high debt, and weak cash conversion pose risks. Analyst sentiment is cautious with 40% buy ratings. Investors should weigh recovery prospects against financial stability concerns.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Manchester United PLC

Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.

Read more on MANU